ClinicalTrials.gg
RecruitingNCT07853508VRUpdated Nov 9, 2026

Effect of Virtual Reality on Pain and Anxiety in Women With Dysmenorrhea

An interventional study of Virtual Reality in Primary Dysmenorrhea, Menstrual Pain and Anxiety, sponsored by Tokat Gaziosmanpasa University. Recruiting at 2 sites in Turkey (Türkiye). Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Tokat Gaziosmanpasa University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Dysmenorrhea with a site in Turkey — 19 open to participants now, 23 under way, none of them phase 3. Dysmenorrhea · Turkey.

Planned enrollment
29th of 72
68 · median 60
Started
2026
with 8 others
No phase
70 of 81
16 open now
Primary completion
2026-10
later than 19 of 22 live
Registered
81st of 81
by date
Lead sponsor
3 of 81
Tokat Gaziosmanpasa University

Among the 81 studies in Dysmenorrhea with a site in Turkey, this one is the 29th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2026, is one of 70 with no phase, reaches primary completion later than 19 of the 22 other live ones, and was the 81st registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

19 of the 81 studies in Dysmenorrhea with a site in Turkey are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Dysmenorrhea with a site in Turkey, or all of them as a file.
02

Study summary

Dysmenorrhea, or painful menstrual periods, is a common condition that can affect daily activities and quality of life. This study aims to evaluate whether using virtual reality (VR) can reduce pain and anxiety in women with primary dysmenorrhea.

Participants will be randomly assigned to either a VR group or a 2D video group. Participants in the VR group will watch a relaxing virtual environment using a VR headset for 20 minutes once a day for three consecutive days. Participants in the 2D video group will watch the same content for the same duration and frequency using a 2D screen, such as a phone, tablet, or computer.

Pain intensity and anxiety levels will be assessed before and after each session during the three-day intervention. The study will compare changes in pain and anxiety between the two groups to evaluate the effect of VR in women with primary dysmenorrhea.

Read the detailed description

Dysmenorrhea is a common menstrual health problem that may negatively affect physical well-being, psychological status, daily activities, and quality of life. Primary dysmenorrhea occurs in the absence of an underlying pelvic pathology and is commonly characterized by cramping pain during menstruation. Pain associated with dysmenorrhea may also be accompanied by psychological symptoms such as anxiety.

Pharmacological treatments are commonly used to manage dysmenorrhea; however, interest in non-pharmacological approaches has increased because of potential limitations and adverse effects associated with medication use. Virtual reality (VR) is a non-pharmacological and non-invasive approach that may help manage pain by directing attention away from painful stimuli and providing an immersive sensory experience.

The purpose of this randomized controlled trial is to evaluate the effect of a relaxing VR-based intervention on pain intensity and anxiety levels among university students with primary dysmenorrhea. The study will also examine changes in these outcomes across repeated measurements during the three-day intervention period. The findings may contribute to the development of non-pharmacological approaches for managing pain and anxiety associated with primary dysmenorrhea.

03

Conditions studied

  • Primary Dysmenorrhea
  • Menstrual Pain
  • Anxiety

Keywords

  • Primary Dysmenorrhea
  • Virtual Reality
  • Pain
  • Anxiety
  • Women health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • University students,
  • Diagnosed with primary dysmenorrhea,
  • Having a regular menstrual cycle,
  • Willing to participate in the study,
  • Having no vision or hearing problems.

Exclusion criteria

Exclusion Criteria:

  • Individuals diagnosed with secondary dysmenorrhea,
  • Individuals experiencing chronic pelvic pain,
  • Individuals with a psychiatric disorder,
  • Individuals using hormonal therapy,
  • Individuals using analgesics during menstruation,
  • Individuals with visual or hearing impairments,
  • Individuals wishing to withdraw at any stage of the study,
  • Individuals who fill out the forms incompletely or fail to fill them out.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    2D Video

    Participants will watch the same 20-minute relaxation video on a conventional 2D screen (e.g., tablet, smartphone, or computer) once daily for three consecutive days during the first three days of menstruation. Pain intensity and state anxiety will be assessed immediately before and after each session.

    Behavioral: Virtual Reality

  • Experimental
    Virtual Reality

    Participants will receive a 20-minute relaxation video through a virtual reality (VR) headset once daily for three consecutive days during the first three days of menstruation. Pain intensity and state anxiety will be assessed immediately before and after each session.

    Behavioral: Virtual Reality

Interventions

  • BehavioralVirtual Reality

    A 20-minute relaxation video will be presented using a virtual reality (VR) headset. Participants will receive the intervention once daily for three consecutive days during the first three days of menstruation. The VR environment is designed to provide an immersive visual and auditory experience and to direct participants' attention away from menstrual pain.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS)

    This is used to quantify certain values that cannot be measured numerically. The two extremes of the parameter being evaluated are marked at either end of a 100 mm line, and the patient is asked to indicate their current status on this line by drawing a mark, placing a dot, or pointing. For pain assessment, "no pain" is written at one end and "severe pain" at the other; the patient then marks their current pain level on the line. The distance from the "no pain" end to the patient's mark represents the level of pain. Evaluation is performed by calculating the mean of the values obtained from the patients.

    Time frame: 1-3. days

Secondary outcomes

  1. State Anxiety Inventory (STAI-X)

    The State-Trait Anxiety Inventory (STAI) form, developed by Spielberger (1983), is used for adults aged 18-69 and consists of 20 items measuring the intensity of anxiety as an emotional state (state anxiety). Responses on the scale are rated as follows: 1: not at all, 2: somewhat, 3: very much, and 4: completely. If more than three items are left unanswered, the completed form is considered invalid and is not scored. Direct items express negative emotions, while reverse-scored items express positive emotions. During scoring, items with a weight of 1 are converted to 4, and those with a weight of 4 are converted to 1. The state anxiety scale contains ten reverse-scored items: items 1, 2, 5, 8, 10, 11, 15, 16, 19, and 20. Theoretically, the obtained scores range from 20 to 80. A high score indicates a high level of anxiety, while a low score indicates a low level of anxiety (Spielberger, 1983). The scale was adapted for Turkish culture by Öner and Le Compte, and reliability and validity

    Time frame: 1-3. days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. De-identified aggregate data will be reported in publications resulting from this study.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2026 to primary completion in Oct 2026, 1 month.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 1, 2026
StartActual
Sep 30, 2026
Primary completionActual
Oct 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
Tokat Gaziosmanpasa University is now Recruiting
Nov 9, 2026
Interventions
Arm changed 2D Video Group→2D Video; Virtual Reality Group→Virtual Reality
Oct 7, 2026
Title
Effect of Virtual Reality on Pain and Anxiety in Women With Dysmenorrhea: A Randomized Controlled Trial
Oct 7, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 3 updates
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Tokat Gaziosmanpasa University · Erbaa, Turkey (Türkiye)no status→Recruiting
    • Tokat Gaziosmanpasa University · Erbaa, Turkey (Türkiye)no status→Recruiting
    + 2 other changes: verification date and date precision
  2. Oct 7, 2026
    Interventions Arm changed 2D Video Group→2D Video; Virtual Reality Group→Virtual Reality
    Title Effect of Virtual Reality on Pain and Anxiety in Women With Dysmenorrhea: A Randomized Controlled Trial
    + 1 other change: verification date
  3. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853508
Responsible party
Abdurrahim UYANIK (Lecturer, Tokat Gaziosmanpasa University) — Principal investigator
First posted
Oct 1, 2026
Start date
Sep 30, 2026
Primary completion
Oct 30, 2026
Completion
Nov 30, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Abdurrahim Uyanık, MSc
Contact
abdurrahim.uyanik@gop.edu.tr
05419634590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion